Resources

For the latest in biologics & tides, sign up for our monthly newsletter to be among the first to receive exclusive insights, in-depth market analyses, and expert articles directly to your inbox

Antibody & Protein Engineering

T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group addressing ‘T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Oligo Chemistry

Optimising Oligonucleotide Therapies: Efficacy, Targetability, and Precision Medicine

With efficacy, safety, and targetability being the top three challenges facing the nucleotide-based therapeutic industry today, will oligo-based therapies fulfil their potential as a clinical modality?
Oligo Chemistry

Oligonucleotide Chemistry & Therapeutics Symposium: Market Trends and Industry Challenges

The first of its kind, the Oligonucleotides: Chemistry & Therapeutics Symposium was a hit. We sat down with an advisory group of leading industry experts to hear their thoughts on the future of the Oligonucleotide drug industry as well as some of its key market trends and challenges.
Oligo Chemistry

Characterisation of Therapeutic Oligonucleotides in Early Drug Discovery

Oligonucleotides are fast becoming a globally recognised form of therapeutic treatment. But how easy is it to analyse them? Director of AstraZeneca, Tomas Leek takes us through the analytic challenges of the early-stage oligonucleotide characterisation.
NextGen Therapeutics

Harnessing Bispecific T Cell Engagers and T Cell Primers in Cancer Treatment

Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?
Peptide Chemistry

Peptides Green Chemistry Strategies and Methods

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our January Discussion Group addressing ‘Peptides Green Chemistry Strategies and Methods’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
NextGen Therapeutics

Bispecific and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Bi-and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
NextGen Therapeutics

A New Cancer-Killing Bispecific Antibody Working Toward the Clinic in 2022

The joint development project by Alligator Bioscience and Aptevo Therapeutics, ALG.APV-527, shows potential in targeting solid tumours
Peptide Chemistry

Advancing Peptide Therapeutics and Personalised Cancer Vaccines

In this Insight Article, we explore the future possibilities, challenges, and solutions in peptide purification and the delivery of precision medicine for immunotherapy.
Peptide Chemistry

Peptides Congress: Market Trends and Industry Challenges

What are the key market trends and challenges facing the Peptides therapeutic industry today? We sat down with an advisory group of leading pharmaceutical and academic experts to discuss our latest Peptides Congress and the interesting insights it disclosed.

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biologics